Glycosyn sues Abbott over infant formula method

Biotech company Glycosyn has sued Abbott Laboratories for allegedly infringing its patented method for manufacturing a key ingredient in infant formula milk, found in three of Abbott’s infant formula products under the Similac brand.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Abbott sues former employee for alleged trade secrets theft

1 June 2023 Ex-scientist faces lawsuit for allegedly downloading thousands of files before leaving for a rival | Abbott seeks damages for ‘flagrant misconduct’ brought to its attention by successive employer.

Americas

AbbVie, Abbott fight bid to force FTC discovery disclosure

6 April 2021 Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.

Americas

Abbott unit prevails in dispute over catheter patent

25 March 2021 In a win for a subsidiary of Abbott Laboratories, St Jude Medical, a US federal court has ruled that it did not infringe a patent for a catheter system owned by Niazi Licensing.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Glycosyn sues Abbott over infant formula method

More on this story

Editor's picks

Editor's picks

More features